Category: Biotechnology company
Quick infos Headquarters: Vancouver, Washington, United States Trade prices Volume: Market Cap: 139.05M Prev closed: 0.41 Open: 0.42 High: 0.47 Low: 0.42 52 week low: 0.055 52 week high: 0.71 Dividends: No Dividends Next ER: April 17, 2023 Before Market Opens
Company Profile We are a biotechnology company focused on developing innovative treatments for multiple therapeutic indications. Our lead candidate Leronlimab (PRO 140) belongs to a new class of therapeutics called viral-entry inhibitors and is one of the most advanced experimental monoclonal antibodies for HIV treatment.
Earnings History Date EPS / Forecast Revenue / Forecast May 3, 2023 -0.02 / -- / - February 1, 2023 - / -0.04- / -January 9, 2023 -0.03 / -0.04- / -November 2, 2022 -0.03 / -0.05- / -August 3, 2022 -0.15 / -0.04- / -view more
Historical Data Date Price Open High Low Vol Change ER Apr 19, 2022 0.2550 0.2599 0.2650
0.2501
1.64M 1.47% Apr 18, 2022 0.2513 0.2700 0.2750
0.2500
3.08M -5.17% Apr 14, 2022 0.2650 0.3075 0.3100
0.2600
4.75M -11.64% Apr 13, 2022 0.2999 0.2800 0.2999
0.2620
3.06M 13.17% Apr 12, 2022 0.2650 0.2761 0.2851
0.2621
3.31M -6.09% Apr 11, 2022 0.2822 0.3000 0.3100
0.2801
1.84M -7.51% Apr 8, 2022 0.3051 0.3100 0.3300
0.2800
3.49M -6.12% Apr 7, 2022 0.3250 0.3550 0.3550
0.3150
1.37M -7.17% Apr 6, 2022 0.3501 0.3650 0.3650
0.3420
2.02M -2.07% Apr 5, 2022 0.3575 0.3701 0.3750
0.3502
736.48K -2.99% view more
NYSE - New York Stock Exchange
More profiles and info about the company News
CytoDyn hit by clinical holds on HIV and COVID-19 programs in the U.S. seekingalpha.com Mar 31, 2022 5:09 am Morgan Stanley projects about a third of biotechs will need financing in 2022 seekingalpha.com Mar 27, 2022 Long COVID, the next frontier for vaccine and drug developers seekingalpha.com Mar 26, 2022 1:36 am Short-term bounce for CytoDyn following CEO ousting not enough to stop slide seekingalpha.com Jan 31, 2022 11:38 pm Ousting of CytoDyn CEO Pourhassan boosts stock; shares up 12% seekingalpha.com Jan 27, 2022 1:30 am CytoDyn announces change in leadership to support approval and commercialization of leronlimab seekingalpha.com Jan 26, 2022 7:15 am CytoDyn's leronlimab in 350 mg weekly dose met endpoints in Phase 2 NASH trial seekingalpha.com Jan 5, 2022 10:38 pm CytoDyn receives positive response from FDA for Phase 3 leronlimab study in COVID-19 seekingalpha.com Dec 21, 2021 10:28 pm CytoDyn files for expanded access use of leronlimab for HIV patients seekingalpha.com Dec 9, 2021 10:13 pm CytoDyn reports leronlimab data in NASH trial for first 15 patients seekingalpha.com Nov 24, 2021 11:08 pm CytoDyn submits the first section of HIV BLA to FDA under rolling review seekingalpha.com Nov 16, 2021 8:07 pm CytoDyn submits leronlimab Breakthrough Therapy designation application to the FDA seekingalpha.com Nov 8, 2021 8:50 pm CytoDyn posts preliminary results from mid-stage leronlimab NASH study seekingalpha.com Nov 3, 2021 6:11 pm CytoDyn treats first patient in late-stage leronlimab Brazil COVID-19 trial seekingalpha.com Oct 25, 2021 6:26 pm CytoDyn says Court ruled activist group’s nominations were Invalid seekingalpha.com Oct 14, 2021 7:52 pm CytoDyn announces legal actions against its former CRO, Amarex Clinical Research seekingalpha.com Oct 7, 2021 7:10 pm CytoDyn launches leronlimab study with immune checkpoint blockade for breast cancer seekingalpha.com Oct 7, 2021 6:55 pm CytoDyn activists send Ziff/Bain Capital presentation critical of CEO to shareholders seekingalpha.com Oct 4, 2021 10:35 pm Cytodyn management calls activist group leronlimab plan 'misguided' and 'misleading' seekingalpha.com Sep 29, 2021 9:07 pm CytoDyn shareholder group unveils plan to obtain cancer therapy approval for Leronlimab seekingalpha.com Sep 24, 2021 8:52 pm This company doesn't provide a dividend.
Talk about CytoDyn below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal .
Buy on Amazon Graham's philosophy of "value investing" has made The Intelligent Investor the stock market bible ever since its original publication in 1949.
The best book on investing ever written.
